READ OUR 2025 REPORT TO READERS

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

53.84 -0.41 (-0.76%)
Streaming Delayed Price Updated: 10:49 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals ↗
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors. 
Via Chartmill
News headline image
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
From QIAGEN N.V.
Via Business Wire
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Qiagen Earnings Review: Q4 Summary ↗
 
Via Benzinga
News headline image
Qiagen: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 5, 2025 ↗
 
Via Benzinga
News headline image
QIAGEN announces plans for transition in leadership of Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance ↗
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%. 
Via Benzinga
News headline image
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
Via ACCESS Newswire
News headline image
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
From QIAGEN N.V.
Via Business Wire
News headline image
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62% ↗
Via The Motley Fool
News headline image
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN delivers solid Q4 2024 growth ahead of outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article